Brief: Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts In Phase 1b Trial Of ORIC-114 In Patients With Mutated NSCLC
15/04/2024 22:15
April 15 (Reuters) - Oric Pharmaceuticals Inc ORIC.O :
* ORIC PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED ACROSS
THREE
EXPANSION COHORTS IN PHASE 1B TRIAL OF ORIC-114 IN PATIENTS WITH
MUTATED NSCLC
* ORIC PHARMACEUTICALS INC - EXPECT TO REPORT UPDATED PHASE
1B
DATA IN FIRST HALF OF 2025
Source text for Eikon: ID:nGNX4LLGrF
Further company coverage: ORIC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ORIC Pharmaceuticals
See all newsBrief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows